Business & Finance
Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
Key Points
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.